Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2165249 | 0.85 | KDM4E (0.39) | AKR1C3AKR1C2ADRB2KDM4EADRB1 | |
| SCHEMBL1205507 | 0.84 | ADRB2 (0.49) | AKR1C3AKR1C2ADRB2KDM4EADRB1 | |
| SCHEMBL1205598 | 0.78 | AKR1C3 (0.38) | AKR1C3AKR1C2ADRB2KDM4EADRB1 | |
| SCHEMBL2165615 | 0.73 | AKR1C3 (0.43) | AKR1C3AKR1C2 | |
| SCHEMBL4494502 | 0.73 | GRM8 (0.40) | AKR1C3AKR1C2 | |
| SCHEMBL2167207 | 0.72 | NOS3 (0.42) | KDM4E | |
| SCHEMBL2163983 | 0.72 | HTR2B (0.39) | AKR1C3AKR1C2KDM4E | |
| SCHEMBL3518571 | 0.71 | KDM6B (0.39) | AKR1C3AKR1C2ADRB2KDM4EAKR1C4 | |
| SCHEMBL3518576 | 0.71 | KDM6B (0.39) | AKR1C3AKR1C2ADRB2KDM4EAKR1C4 | |
| SCHEMBL8809419 | 0.68 | KDM4E (0.40) | AKR1C3AKR1C2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528129-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | AKR1C3 884/4885AKR1C2 1483/4885ADRB2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.